Physician
Psychiatry
Dr. Jerrold F. Rosenbaum, MD
Jerrold Rosenbaum practices Psychiatry. He went to medical school at Yale University School of Medicine. Yale University School of Medicine is a top medical university. Yale University School of Medicine is ranked 7 in research and 57 in primary care medicine He over the years received 14 awards: "Super Doctor", "Distinguished Lecturer", "Outstanding Psychiatrist in Research", "Nominee, 2011-2012 Harold Amos Faculty Diversity Award", "Friend & Leader Award", "Castle Connolly Americas Top Doctor 5 years in a row", "Top doctors for women", "C. Charles Burlingame Award", "Distinguished Investigator Award", "Americas Top Doctors", "Best Doctors", "Best Doctors in America", "Dunlop Award, Psychiatry Service" and "Ethel Dupont-Warren Fellowship in Psychiatry". Jerrold Rosenbaum is a published doctor as well. He has 52 publications published. The latest was: Stratifying Risk for Renal Insufficiency Among Lithium-Treated Patients: An Electronic Health Record Study. He accepts Medicare.
Publications
- Stratifying Risk for Renal Insufficiency Among Lithium-Treated Patients: An Electronic Health Record Study.
- The Human Ortholog of Acid-Sensing Ion Channel Gene ASIC1a Is Associated with Panic Disorder and Amygdala Structure and Function.
- Conditional Probability of Response or Nonresponse of Placebo Compared With Antidepressants or St John's Wort in Major Depressive Disorder.
- Methodological Challenges of Moving Beyond DSM Categories: Transdiagnostic Studies of Frontolimbic Connectivity Changes in Vulnerable Individuals.
- Psychopathology in adolescent offspring of parents with panic disorder, Major depression, or both: a 10-year follow-up.
- Recollections from the ADAA President.
- Cognitive behavioral therapy for 4- to 7-year-old children with anxiety Disorders: a randomized clinical trial.
- Risk factors for fatal and nonfatal repetition of suicide attempt: a critical appraisal.
- Assuring that double-blind is blind.
- Conflict of interest-- an issue for every psychiatrist.
- Executive functioning in offspring at risk for depression and anxiety.
- The history and current state of antidepressant clinical trial design: A call to action for proof-of-concept studies.
- It is time to take a stand for medical research and against terrorism targeting medical scientists.
- Influence of RGS2 on anxiety-related temperament, personality, and brain function.
- The child behavior checklist broad-band scales predict subsequent psychopathology: A 5-year follow-up.
- Clinical outcomes of laboratory-observed preschool behavioral disinhibition at five-year follow-up.
- Behavioral inhibition in preschool children at risk is a specific predictor of middle childhood social anxiety: a five-year follow-up.
- Posttraumatic stress Disorder symptoms following media exposure to tragic events: impact of 9/11 on children at risk for anxiety Disorders.
- Early symptomatic worsening during treatment with fluoxetine in Major depressive disorder: prevalence and implications.
- Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report.
- Update on trends in antidepressant use: Upswing in 2006 Following Period of Decline.
- Antecedents to panic Disorder in nonreferred adults.
- Laboratory-observed behavioral disinhibition in the young offspring of parents with bipolar Disorder: a high-risk pilot study.
- A Double-blind, randomized trial of St John's wort, fluoxetine, and placebo in Major depressive disorder.
- Childhood antecedents to panic Disorder in referred and nonreferred adults.
- The corticotropin-releasing hormone gene and behavioral inhibition in children at risk for panic Disorder.
- Attitudes toward benzodiazepines over the years.
- Patterns of comorbidity in panic disorder and Major depression: findings from a nonreferred sample.
- Parental predictors of pediatric panic Disorder/agoraphobia: a controlled study in high-risk offspring.
- Serum cholesterol in the continuation phase of pharmacotherapy with fluoxetine in remitted Major depressive disorder.
- Serum folate, vitamin B12, and homocysteine in Major depressive disorder, Part 1: predictors of clinical response in fluoxetine-resistant depression.
- Serum folate, vitamin B12, and homocysteine in Major depressive disorder, Part 2: predictors of relapse during the continuation phase of pharmacotherapy.
- Effect of medical comorbidity on response to fluoxetine augmentation or dose increase in outpatients with treatment-resistant depression.
- Lack of association between behavioral inhibition and psychosocial adversity factors in children at risk for anxiety Disorders.
- Ziprasidone augmentation of selective serotonin reuptake inhibitors (SSRIs) for SSRI-resistant Major depressive disorder.
- A preliminary open study of the tolerability and effectiveness of nefazodone in Major depressive disorder: comparing patients who recently discontinued an SSRI with th...
- The development of clonazepam as a psychotropic: the massachusetts general hospital experience.
- Pregnancy complications associated with childhood anxiety Disorders.
- Association of a genetic marker at the corticotropin-releasing hormone locus with behavioral inhibition.
- Serotonin transporter polymorphisms and adverse effects with fluoxetine treatment.
- Background and rationale for the sequenced treatment alternatives to relieve depression (STAR*D) study.
- Behavioral inhibition and disinhibition as hypothesized precursors to psychopathology: implications for pediatric bipolar Disorder.
- Rationale, design, and methods of the systematic treatment enhancement program for bipolar Disorder (STEP-BD).
- Fluoxetine treatment of depressed patients with comorbid anxiety Disorders.
- Double-blind study of high-dose fluoxetine versus lithium or desipramine augmentation of fluoxetine in partial responders and nonresponders to fluoxetine.
- Selecting methodologies for the evaluation of differences in time to response between antidepressants.
- Effect of abrupt change from standard to low serum levels of lithium: a reanalysis of double-blind lithium maintenance data.
- Temperamental correlates of disruptive behavior Disorders in young children: preliminary findings.
- Escitalopram: a second-generation SSRI.
- Conclusion: the future of single-isomer pharmacology.
- Strategies for treatment of SSRI-associated sexual dysfunction: a survey of an academic psychopharmacology practice.
Schools
Yale University
Denver General Hospital
Massachusetts General Hospital
Conditions Treated
- Major Depressive Disorder
- Phobia
Doctors Specialties
Accepted Insurances
Awards
- Super Doctor
- Distinguished Lecturer
- Outstanding Psychiatrist in Research
- Nominee, 2011-2012 Harold Amos Faculty Diversity Award
- Friend & Leader Award
- “Castle Connolly America’s Top Doctor†5 years in a row
- Top doctors for women
- C. Charles Burlingame Award
- Distinguished Investigator Award
- America’s Top Doctors
- Best Doctors
- Best Doctors in America
- Dunlop Award, Psychiatry Service
- Ethel Dupont-Warren Fellowship in Psychiatry
Education
-
Massachusetts General Hospital
-
Yale University School of Medicine
Hospital
-
Massachusetts General Hospital
Drug Facts
| NPI NUMBER |
|
1972586949 |
| NPPES Provider LastName |
|
ROSENBAUM |
| NPPES Provider FirstName |
|
JERROLD |
| NPPES Provider ZIPCode |
|
021143117 |
| NPPES Provider State |
|
MA |
| Specialty Description |
|
Psychiatry |
| Total Claim Count |
|
327.0 |
| Distinct Opioid Count |
|
2.0 |
| Opioid Claim Count |
|
24.0 |
| Percent Opioid Claims |
|
7.34 |
Helpful Reviews
Give
Anonymous Review
Medicare Facts
| National Provider Identifier [NPI] |
1972586949 |
| Last Name Of The Provider |
ROSENBAUM |
| First Name Of The Provider |
JERROLD |
| View All |
|
Similar Doctors
Doctor Directory | TOS | twitter | FB | Angel | blog
This Doctor is OpenDoctor Recommended.